Jci_page_head_homepage_01 Jci_page_head_homepage_02
Frances A. High, Maozhen Zhang, Aaron Proweller, LiLi Tu, Michael S. Parmacek, Warren S. Pear, Jonathan A. Epstein
Published in Volume 117, Issue 2
J Clin Invest. 2007; 117(2):353–363 doi:10.1172/JCI30070
Abstract | Full text | PDF | Supplemental material
Options: View larger image (or click on image)
Jci0730070
Figure 6
Inhibition of Notch activity blocks the differentiation of neural crest precursors into smooth muscle ex vivo.

(AC) Neural tube explants from E8.5 control (A) and Pax3Cre/+ DNMAML (B and C) embryos, immunostained for α-SMA (green) and GFP (red). The majority of cells in the control explant express α-SMA, as do the DNMAML-GFP–negative cells in the Pax3Cre/+ DNMAML explants (B and C). Conversely, most of the DNMAML-GFP–positive cells in B and C are α-SMA negative. (DF) Wild-type neural tube explants treated with the γ-secretase inhibitor DAPT, immunostained for α-SMA (green) and SM22α (red). Compared with DMSO-treated controls (D), explants treated with 1 μM DAPT (E) or 5 μM DAPT (F) show a decrease in the number of cells expressing smooth muscle markers. (G) Quantification of neural tube explant assays from Pax3Cre/+R26RGFP (control) and Pax3Cre/+ DNMAML embryos. (H) Quantification of assays on neural tube explants treated with the γ-secretase inhibitor DAPT. Error bars indicate 1 SD. P values, indicated by brackets, were determined by Student’s t test. Scale bars: 100 μm.